Spots Global Cancer Trial Database for Oral Aromatase Inhibitors Modify the Gut Microbiome

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Oral Aromatase Inhibitors Modify the Gut Microbiome

Official Title: Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability

Study ID: NCT05030038

Conditions

Breast Cancer

Interventions

Fecal swab collection

Blood samples

Study Description

Brief Summary: The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.

Detailed Description: Primary Objective: To describe the microbiome shift of gut microbiome from baseline after 4-weeks and 12-weeks of oral aromatase inhibitor treatment. Secondary Objective * To correlate gut microbiome populations with circulating sex hormone metabolite concentrations at baseline and 12 weeks. * To describe the correlation of change in the microbiome populations with change in circulating sex hormone metabolite concentrations from baseline to 12 weeks.